Outcomes of Focal Ablation for Prostate Cancer

Description

This study will be designed to define the efficacy and safety of ablative therapies in the management of localized prostate cancer and comprehensively evaluate quality of life outcomes and oncologic control following treatment.

Conditions

Prostate Cancer

Talk to us

Study Overview

On this page

Study Details

Study overview

This study will be designed to define the efficacy and safety of ablative therapies in the management of localized prostate cancer and comprehensively evaluate quality of life outcomes and oncologic control following treatment.

Prospective Single Institutional Study Evaluating the Outcomes for Patients Undergoing Ablative Therapies in the Management of Clinically Localized Prostate Cancer in the Primary and Salvage Setting

Outcomes of Focal Ablation for Prostate Cancer

Condition
Prostate Cancer
Intervention / Treatment

-

Contacts and Locations

Dallas

UTSW, Dallas, Texas, United States, 75390

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Men with histologically confirmed prostate adenocarcinoma diagnosed on prostate biopsy
  • * Men with histologically confirmed local recurrence of prostate cancer diagnosed on prostate biopsy and standard of care imaging excluding locoregional or metastatic disease
  • * Age 18-90 years.
  • * Life expectancy \> 1 year
  • * Ability to understand and the willingness to sign a written informed consent.
  • * Anatomic abnormalities that do not allow for focal ablation
  • * Evidence of non-organ confined disease that is not feasible for ablation
  • * Has active urinary traction infection

Ages Eligible for Study

18 Years to 90 Years

Sexes Eligible for Study

MALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Texas Southwestern Medical Center,

Xiaosong Meng, MD, PhD, PRINCIPAL_INVESTIGATOR, UT Southwestern Medical Center

Study Record Dates

2026-08